Swedbank AB Acquires 71,200 Shares of Vera Therapeutics, Inc. $VERA

Swedbank AB grew its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 142.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 121,200 shares of the company’s stock after purchasing an additional 71,200 shares during the period. Swedbank AB owned about 0.19% of Vera Therapeutics worth $6,138,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of VERA. Vestal Point Capital LP increased its holdings in shares of Vera Therapeutics by 24.0% in the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after purchasing an additional 600,000 shares in the last quarter. Integral Health Asset Management LLC increased its holdings in shares of Vera Therapeutics by 47.8% in the 3rd quarter. Integral Health Asset Management LLC now owns 1,700,000 shares of the company’s stock worth $49,402,000 after purchasing an additional 550,000 shares in the last quarter. Braidwell LP bought a new stake in shares of Vera Therapeutics in the 3rd quarter worth $13,738,000. Armistice Capital LLC increased its holdings in shares of Vera Therapeutics by 294.1% in the 3rd quarter. Armistice Capital LLC now owns 536,000 shares of the company’s stock worth $15,576,000 after purchasing an additional 400,000 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Vera Therapeutics by 11.9% in the 4th quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock worth $180,805,000 after purchasing an additional 379,748 shares in the last quarter. Institutional investors own 99.21% of the company’s stock.

Insider Activity at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $36.74, for a total value of $679,690.00. Following the completion of the sale, the chief executive officer owned 216,744 shares of the company’s stock, valued at $7,963,174.56. The trade was a 7.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is owned by insiders.

Vera Therapeutics Stock Performance

Shares of VERA opened at $34.34 on Wednesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64. Vera Therapeutics, Inc. has a one year low of $18.76 and a one year high of $56.05. The firm has a market capitalization of $2.46 billion, a P/E ratio of -6.20 and a beta of 0.96. The business has a fifty day moving average of $38.76 and a 200 day moving average of $41.02.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period in the prior year, the company earned ($0.81) earnings per share. As a group, sell-side analysts anticipate that Vera Therapeutics, Inc. will post -6.14 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. HC Wainwright lifted their target price on Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a report on Monday, April 20th. Evercore set a $91.00 price objective on Vera Therapeutics in a report on Friday, May 15th. Finally, Wolfe Research raised Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price objective for the company in a report on Wednesday, March 11th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Vera Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $79.00.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.